强生公司周六表示，其实验性每日一次口服前列腺癌新药在早期试验中使肿瘤消失或缩小。
Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial.
强生去年通过以30.5亿美元收购Halda Therapeutics获得了该药物的使用权。以下是更多细节：该公司在接受过多种治疗的晚期前列腺癌患者中测试JNJ-6143。其新颖的作用机制通过干扰癌细胞生存所需的一种蛋白质，选择性地杀死癌细胞。在试验中，接受50毫克剂量的31例可评估患者中，77%的患者前列腺特异性抗原（PSA，一种用于监测前列腺癌的血液标志物）水平下降至少50%；48%的患者PSA水平下降至少90%。在可通过影像学测量肿瘤的患者中，69%经确认达到完全或部分缓解。
J&J had gained access to the drug through its $3.05 billion deal to buy Halda Therapeutics last year.
“它为强生的前列腺癌产品组合增加了一种新的作用机制，”强生发言人表示。
Here are more details:
常见副作用为恶心以及胆固醇和甘油三酯水平升高。一名患者因不良反应停止治疗。相关数据在欧洲肿瘤内科学会大会上公布。
The company was testing JNJ-6143 in patients with advanced prostate cancer who had received multiple treatments Its novel approach selectively kills cancer cells by interfering with a protein they need to survive In the trial, 77% of 31 evaluable patients receiving the 50-milligram dose saw their PSA levels, a blood marker used to monitor prostate cancer, fall by at least 50%; in 48% of patients, PSA levels fell by at least 90% Among patients whose tumors could be measured using imaging, 69% had a confirmed complete or partial response "It adds a new mechanism of action to J&J's prostate cancer portfolio," a Johnson & Johnson spokesperson said Common side effects were nausea and elevated cholesterol and triglyceride levels. One patient discontinued treatment due to adverse effects The data were presented at the European Society for Medical Oncology Congress